A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kagawa University

Criteria

Inclusion Criteria:

• IgA nephropathy confirmed by renal biopsy

• Hypertension (<= 125/75 mmHg)

Exclusion Criteria:

• Patients who have been treated with angiotensin type 1 receptor blocker or angiotensin-converting enzyme inhibitor within 4 weeks

• Severe hypertension (<= 180/110 mmHg) or secondary hypertension

• Patients with history of allergy or adverse effect for aliskiren

• Renal dysfunction (estimated Glomerular Filtration Rate < 60 mL/min/1.73m2)

• Pregnancy

• Patient treated with cyclosporine

• Hyperkalemia (serum potassium >= 5.6 mmol/L)

• Autoimmune disease including systemic lupus erythematosus

• Patients inadequate for the study